A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER MASTER PROTOCOL TO EVALUATE THE EFFICACY AND SAFETY OF ELECOGLIPRON IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH OR WITHOUT TYPE 2 DIABETES MELLITUS (EMBOLD)

Intervention/treatment:
ELECOGLIPRON (AZD5004)
Medical condition:
OVERWEIGHT/OBESITY
Protocol code:
D7260C00015
Control number:
501114
Status:
Recruiting
Approved:
May 12, 2026
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT07667803
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
AstraZeneca Clinical Study Information Center
Role
CONTACT
Phone:
1-877-240-9479
Sponsor
ASTRAZENECA CANADA INC

Locations

Alberta

Research Site
Calgary, Alberta, T2V 4J2
NOT_YET_RECRUITING
Research Site
Calgary, Alberta, T3R 1W9
NOT_YET_RECRUITING

British Columbia

Research Site
Vancouver, British Columbia, V5Y 3W2
NOT_YET_RECRUITING
Research Site
Victoria, British Columbia, V8V 4A1
NOT_YET_RECRUITING

New Brunswick

Research Site
Moncton, New Brunswick, E1G 1A7
NOT_YET_RECRUITING

Nova Scotia

Research Site
Truro, Nova Scotia, B2N 1L2
RECRUITING

Ontario

Research Site
Brampton, Ontario, L6T 0G1
NOT_YET_RECRUITING
Research Site
Hamilton, Ontario, L8L 5G8
NOT_YET_RECRUITING
Research Site
Niagara Falls, Ontario, L2H 1H5
NOT_YET_RECRUITING
Research Site
North York, Ontario, M6B 3H7
NOT_YET_RECRUITING
Research Site
Sarnia, Ontario, N7T 4X3
NOT_YET_RECRUITING
Research Site
Scarborough Village, Ontario, M1R 0B1
NOT_YET_RECRUITING
Research Site
Stouffville, Ontario, L4A1H2
NOT_YET_RECRUITING
Research Site
Toronto, Ontario, M3J 0K2
NOT_YET_RECRUITING
Research Site
Toronto, Ontario, M6G 1M2
NOT_YET_RECRUITING
Research Site
Toronto, Ontario, M9V 4B4
RECRUITING

Quebec

Research Site
Joliette, Quebec, J6E 6A9
NOT_YET_RECRUITING
Research Site
Montreal, Quebec, H4N 2W2
NOT_YET_RECRUITING
Research Site
Saint-Lambert, Quebec, J4P 2H4
NOT_YET_RECRUITING
Research Site
Terrebonne, Quebec, J6X 4P7
NOT_YET_RECRUITING
Did you find what you were looking for?